-
Betibeglogene autotemcel, sold
under the
brand name Zynteglo, is a gene
therapy for the
treatment for beta thal****emia. It was
developed by
Bluebird Bio...
- The company's only - in the
European Union (EU) -
approved drug is
betibeglogene autotemcel (Zynteglo),
which treats transfusion-dependent beta thal****emia...
- B06AC05
Lanadelumab B06AC06
Berotralstat B06AX01
Crizanlizumab B06AX02
Betibeglogene autotemcel B06AX03
Voxelotor B06AX04
Mitapivat B06AX05 Exagamglogene...
- 7%. The most
positive results tend to
occur with very
young people.
Betibeglogene autotemcel, sold
under the
brand name Zynteglo, is a gene
therapy for...
- dose,
making it the most
expensive drug ever. In May, the EMA
approved betibeglogene autotemcel (Zynteglo) for
treating beta thal****emia for
people twelve...
- RMAT
designated drugs include the
novel CAR-T
therapy Kymriah and
betibeglogene autotemcel for beta thal****emia. As of 31
March 2021, 62
requests for...
- 8
million in the
United States for its one-time
treatment Zynteglo (
betibeglogene autotemcel). Gene
editing therapies aimed at
increasing fetal hemoglobin...
- B-cell
lymphoma Beremagene geperpavec (Vyjuvek):
treatment of wounds.
Betibeglogene autotemcel (Zynteglo):
treatment for beta thal****emia Brexucabtagene...
- 23%, and
mortality 7%. The best
results are with very
young people.
Betibeglogene autotemcel, sold
under the
brand name Zynteglo, is a gene
therapy for...
-
human arylsulfatase A (ARSA) gene (European
approval granted 2020).
Betibeglogene autotemcel (branded as Zynteglo) for the
treatment of transfusion-dependent...
